Trial intelligence / Profile preview

Tiotropium/salmeterol crossover study in COPD

2007-005135-28Phase 3Completed

Sponsor
Boehringer Ingelheim
Start
Feb 2008
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, randomised, double-blind trial of tiotropium and salmeterol in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Daytime lung function superiority. Started Feb 2008; status: completed.

02

Drugs

tiotropiumsalmeterol
03

Conditions

chronic obstructive pulmonary disease (COPD)

Beyond the preview

Go deeper on 2007-005135-28.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2007-005135-28.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call